In 1876 surgeon Arthur Davy attributed the symptoms to military foot drill where “over-expanding the chest, caused dilatation of the heart, and so induced irritability".During World War I, Sir Thomas Lewis (who had been a member of staff of the Medical Research Committee) studied many soldiers who had been referred to the Military Heart Hospitals in Hampstead and Colchester with disordered action of the heart or valvular disease of the heart. In 1918 he published a monograph summarizing his findings, which showed that the vast majority did not have structural heart disease, as evidenced by the diagnostic methods available at the time. In it, he reviewed the difference in symptoms between effort syndrome and structural heart disease, examined possible causes of effort syndrome, the diagnosis of structural heart disease in soldiers, its outlook and treatment, and lessons learned by the Army. Since then, a variety of similar or partly similar conditions named above have been described. See also
Shell shock
Combat fatigue
Takotsubo cardiomyopathy
Postural orthostatic tachycardia syndrome
Soldiers Heart (novel)

References


== External links ==
Management
Gene therapy
As achromatopsia is linked to only a few single-gene mutations, it is a good candidate for gene therapy. Gene therapy is a technique for injecting functional genes into the cells that need them, replacing or overruling the original alleles linked to achromatopsia, thereby curing it - at least in part. Achromatopsia has been a focus of gene therapy since 2010, when achromatopsia in dogs was partially cured. Several clinical trials on humans are ongoing with mixed results. Eyeborg
Since 2003, a cybernetic device called the eyeborg has allowed people to perceive color through sound waves. This form of Sensory substitution maps the hue perceived by a camera worn on the head to a pitch experienced through bone conduction according to a sonochromatic scale. This allows achromats (or even the totally blind) to perceive - or estimate - the color of an object. Achromat and artist Neil Harbisson was the first to use the eyeborg in early 2004, which allowed him to start painting in color. He has since acted as a spokesperson for the technology, namely in a 2012 TED Talk. A 2015 study suggests that achromats who use the Eyeborg for several years exhibit neural plasticity, which indicates the sensory substitution has become intuitive for them. Other accommodations
While gene therapy and the Eyeborg may currently have low uptake with achromats, there are several more practical ways for achromats to manage their condition:

Some colors can be estimated through the use of colored filters.